Login to Your Account



Chroma Pact with GSK Carries $1B Potential

By Nuala Moran


Wednesday, June 24, 2009
LONDON - Chroma Therapeutics Ltd. landed a deal boasting a headline value of $1 billion with GlaxoSmithKline (GSK) plc, in which Chroma will apply its chemical motif technology for targeting small molecules directly into macrophages, to develop treatments for autoimmune and other inflammatory diseases. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription